[Hepatocellular carcinoma and vitamin K2].
Despite recent progress in diagnosis and therapy, hepatocellular carcinoma(HCC)remains among the cancers with the poorest prognoses. Vitamin Ks(VKs)have been shown to suppress the growth of HCC cells. Long-term administration of VK2 has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK2 against HCC, co-administration of VK2 with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.
Internal Medicine, Imari-Arita Kyoritsu Hospital, Japan.
Toshihiko
T
Mizuta
Health Administration Center, Saga University, Japan.
Iwata
I
Ozaki
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D015398:Signal Transduction / Q000187:drug effects; D024482:Vitamin K 2 / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D024482:Vitamin K 2